VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Down 38.1% in February

VolitionRX Limited (NYSEAMERICAN:VNRX) was the target of a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 1,421,157 shares, a decline of 38.1% from the February 12th total of 2,294,782 shares. Based on an average daily volume of 2,150,188 shares, the days-to-cover ratio is currently 0.7 days. Currently, 1.1% of the shares of the stock are sold short. Currently, 1.1% of the shares of the stock are sold short. Based on an average daily volume of 2,150,188 shares, the days-to-cover ratio is currently 0.7 days.

Hedge Funds Weigh In On VolitionRX

Several institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC raised its position in VolitionRX by 166.6% in the 4th quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after purchasing an additional 67,848 shares during the period. Squarepoint Ops LLC purchased a new stake in VolitionRX during the fourth quarter valued at about $34,000. Jane Street Group LLC bought a new position in shares of VolitionRX during the fourth quarter valued at about $28,000. Geode Capital Management LLC grew its stake in shares of VolitionRX by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after buying an additional 85,816 shares during the last quarter. Finally, Armistice Capital LLC increased its holdings in shares of VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after buying an additional 887,351 shares during the period. Institutional investors own 8.09% of the company’s stock.

VolitionRX Stock Down 2.9%

Shares of NYSEAMERICAN VNRX traded down $0.01 during trading hours on Friday, reaching $0.19. 1,422,783 shares of the stock traded hands, compared to its average volume of 1,611,816. The company’s 50-day simple moving average is $0.25 and its two-hundred day simple moving average is $0.37. The company has a market capitalization of $25.81 million, a P/E ratio of -0.83 and a beta of 1.34. VolitionRX has a 52-week low of $0.17 and a 52-week high of $0.94.

Analyst Ratings Changes

A number of research firms have commented on VNRX. HC Wainwright cut their price target on shares of VolitionRX from $2.50 to $1.50 and set a “buy” rating for the company in a research note on Monday, November 17th. Maxim Group cut shares of VolitionRX from a “buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $3.00 price objective on shares of VolitionRX in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $2.50.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.